Last reviewed · How we verify
NCT06319404
Immune Function of Colorectal Cancer Lymph Nodes
trial in Colorectal Cancer in 500 participants. Status unknown.
1 April 2026
Quick facts
| Lead sponsor | Shanxi Province Cancer Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 500 |
| Start date | 1 April 2024 |
| Primary completion | 1 April 2026 |
| Estimated completion | 1 April 2026 |
Conditions studied
- Colorectal Cancer — all drugs for Colorectal Cancer →
- Lymph Node — all drugs for Lymph Node →
Sponsor
Shanxi Province Cancer Hospital
Who can join
Adults 18 to 75, any sex, with Colorectal Cancer or Lymph Node. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Lymph nodes are very important immune organs in the human body and play an important role in the physiological and pathological activities of the body, especially in anti-tumor immunity. The role of regional draining lymph nodes in the development of colorectal cancer is still unknown. In this study, the role of lymph nodes in the development of colorectal cancer was investigated through multicenter and multi-omics data.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
MRI-Derived Lymph Nodes Morphological and Topological Structure (LNs-MTS) Model for Evaluating Immune Status and Prognosis in Rectal Cancer.
Liu Y, Zhang L, Cui Y, Zhang W, et al · · 2025 · cited 1× · PMID 40886317 · DOI 10.1002/advs.202506523
Verify or expand the search:
- PubMed search for NCT06319404
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Colorectal Cancer
Currently open trials in the same condition.
- NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
- NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
- NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting
Other Shanxi Province Cancer Hospital trials
Trials by the same sponsor.
- NCT07486648 — Osimertinib Plus Capivasertib in NSCLC With PIK3CA/AKT1/PTEN Alterations Following Prior 1L Osimertinib · Phase 1, PHASE2 · not yet recruiting
- NCT06637007 — Phase II Clinical Trial of Chidamide Combined With AK112 for Second-line and Advanced Bone and Soft Tissue Sarcoma · Phase 2 · recruiting
- NCT07489339 — MDT-Based Nursing for Small Cell Lung Cancer During Chemo-Immunotherapy · NA · completed
- NCT06255704 — A Single-arm, Single-center, Open-label Phase II Study of Zanubrutinib Combined With R-CHOP/R-DHAP in Newly Diagnosed Ma · Phase 2 · not yet recruiting
- NCT07490639 — Family-Supported Palliative Care in Advanced Lung Cancer · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06319404 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanxi Province Cancer Hospital
- Last refreshed: 20 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06319404.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing